Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Uveal Melanoma 1Solid Tumor 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Melanoma 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Glioma 1Disease Progression 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Oxaliplatin 13Bevacizumab 11Capecitabine 10Fluorouracil 8Blood Specimen Collection 8Leucovorin 7Cetuximab 7Folfox protocol 6pembrolizumab 5Drug Therapy 5trifluridine tipiracil drug combination 4dostarlimab 4Nivolumab 4Irinotecan 4HMPL-013 4fludarabine 3XELOX 3Specimen Handling 3IFL protocol 3Cyclophosphamide 3Biopsy 3toripalimab 2tislelizumab 2tipiracil 2regorafenib 2pertuzumab 2envafolimab 2encorafenib 2cemiplimab 2atezolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Colonic Neoplasms × Valproic Acid × Clear all
NCT03919292 2026-04-21

Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

Virginia Commonwealth University

Phase 1/2 Recruiting
83 enrolled
Gastrointestinal

Colonic Neoplasms, Pancreatic Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡